Added to YB: 2024-08-29
Pitch date: 2024-08-27
KZR [bullish]
Kezar Life Sciences, Inc.
-2.5%
current return
Author Info
No bio for this author
Company Info
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
Market Cap
$45.1M
Pitch Price
$6.40
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.61
P/E
-0.64
EV/Sales
N/A
Sector
Biotechnology
Category
value
Kezar Life Sciences: A Deep Value Play with Two High-Stakes Catalysts on the Horizon.
KZR: Trading at <30% of net cash ($164M, $46M mkt cap). 2 shots on goal: Zetomipzomib in Lupus Nephritis (mid-2026 readout) & Autoimmune Hepatitis (~6 months). KZR-261 discontinued, reducing burn. $15M-$20M/qtr burn. Restructuring done. Low-cost option on potential biotech success.
Read full article (2 min)